期刊
CANCER RESEARCH
卷 69, 期 10, 页码 4116-4124出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-08-3441
关键词
-
类别
资金
- Kleberg Center for Molecular Markers at MDACC
- Cancer Center Support [CA16672]
- MDACC Physician Scientist Program
- Robert and Janice McNair Foundation
- National Cancer Institute grants [K23-CA121994, R21-CAI20248]
- National Cancer Institute Breast Specialized Program for Research Excellence [P50-CA116199, P50-CA58223-09A1, R01-CA-101227-01]
- National Cancer Institute [CA116199, CA099031]
- Komen Foundation [FAS0703849]
- V Foundation for Cancer Research
- Breast Cancer Research Foundation
- Office of Science, Office of Biological & Environmental Research, U.S. Department of Energy [DE-AC02-05CH11231]
- NIH/National Cancer Institute [P50 CA58207, U54 CA112970]
Metaplastic breast cancers (MBC) are aggressive, chemo-resistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other breast cancer subtypes, 28 MBCs were compared with common breast cancers using comparative genomic hybridization, transcriptional profiling, and reverse-phase protein arrays and by sequencing for common breast cancer mutations. MBCs showed unique DNA copy number aberrations compared with common breast cancers. PIK3CA mutations were detected in 9 of 19 MBCs (47.4%) versus 80 of 232 hormone receptor-positive cancers (34.5%; P = 0.32), 17 of 75 HER-2-positive samples (22.7%; P = 0.04), 20 of 240 basal-like cancers (8.3%; P < 0.0001), and 0 of 14 claudin-low tumors (P = 0.004). Of 7 phosphatidylinositol 3-kinase/AKT pathway phosphorylation sites, 6 were more highly phosphorylated in MBCs than in other breast tumor subtypes. The majority of MBCs displayed mRNA profiles different from those of the most common, including basal-like cancers. By transcriptional profiling, MBCs and the recently identified claudin-low breast cancer subset. constitute related receptor-negative subgroups characterized by low expression of GATA3-regulated genes and of genes responsible for cell-cell adhesion with enrichment for markers linked to stem cell function and epithelial-to-mesenchymal transition (EMT). In contrast to other breast cancers, claudin-low tumors and most MBCs showed a significant similarity to a tumorigenic signature defined using CD44(+)/CD24(-) breast tumor-initiating stein cell-like cells. MBCs and claudin-low tumors are thus enriched in EMT and stem cell-like features, and may arise from an earlier, more chemoresistant breast epithelial precursor than basal-like or luminal cancers. PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets. [Cancer Res 2009;69(10):4116-24]
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据